Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
12 sept. 2024 07h00 HE
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
Quantexa Recognized as Leader in Enterprise and Payment Fraud Solutions in the 2024 Chartis RiskTech Quadrant® For Enterprise Fraud Solutions
09 sept. 2024 06h41 HE
|
Quantexa
Quantexa Recognized as Leader in Enterprise and Payment Fraud Solutions in the 2024 Chartis RiskTech Quadrant® For Enterprise Fraud Solutions
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
05 sept. 2024 16h01 HE
|
Vor Biopharma
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...
Quantexa Recognized as a “Luminary” in Celent’s 2024 Insurance Fraud Detection Solutions Report
04 sept. 2024 05h32 HE
|
Quantexa
Quantexa announced that its Fraud Detection solution has been awarded “Luminary” status in Celent’s 2024 Insurance Fraud Detection Solutions Report.
Senti Bio to Participate in Upcoming Investor Conferences
03 sept. 2024 08h15 HE
|
Senti Biosciences, Inc.
Senti Bio will participate in two upcoming investor conferences in September.
Vor Bio to Participate in Upcoming Investor Conferences
28 août 2024 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
13 août 2024 16h05 HE
|
Senti Biosciences, Inc.
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
05 août 2024 08h05 HE
|
Senti Biosciences, Inc.
Senti Bio announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (CIRM).
USA Bank Secrecy Act (BSA) Compliance Mandates Webinar: Latest Regulatory Developments for Financial Institutions (ON-DEMAND)
09 juil. 2024 04h35 HE
|
Research and Markets
Dublin, July 09, 2024 (GLOBE NEWSWIRE) -- The "BSA Important Issues: new mandates, requirements, and recommendations" report has been added to ResearchAndMarkets.com's offering. The landscape of...
FFIEC Bank Secrecy Act/Anti-Money Laundering Examination Manual Webinar: What Compliance Officers Really Need to Know? (ON-DEMAND)
09 juil. 2024 04h29 HE
|
Research and Markets
Dublin, July 09, 2024 (GLOBE NEWSWIRE) -- The "FFIEC BSA/AML Examination Manual: What Compliance Officers Really Need to Know?" training has been added to ResearchAndMarkets.com's offering.This...